Loading...
Loading...
Browse all stories on DeepNewz
VisitSurge in Wegovy, Zepbound Use to Reduce U.S. Calorie Intake by 10 Quadrillion by 2030
Oct 15, 2024, 01:00 AM
A surge in the use of GLP-1 drugs, including Wegovy and Zepbound, is projected to significantly reduce calorie intake in U.S. adults by 10 quadrillion by 2030, according to a new report. This increase in GLP-1 prescriptions for obesity has been observed alongside a relatively flat prescribing rate for GLP-1s labeled for type 2 diabetes between June and September 2024, as noted in Truveta Research's latest GLP-1 monitoring report.
View original story
Markets
No • 50%
Yes • 50%
Truveta Research's GLP-1 monitoring report or similar industry reports
No • 50%
Yes • 50%
FDA announcements and approval records
Yes • 50%
No • 50%
National Health and Nutrition Examination Survey (NHANES) or similar studies
Other • 25%
Pfizer • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Sales reports from pharmaceutical companies or market analysis firms
Other • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Market analysis reports from sources like IQVIA or Truveta Research
Decrease or no change • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Increase by more than 10% • 25%
Truveta Research's GLP-1 monitoring report or similar industry reports